Skip to main content

Table 3 SGLT-2i prescriptions in type 2 diabetes according to BMI category in individuals with or without heart failure

From: Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis

BMI categorya

SGLT-2i with heart failure

(N = 1157)

SGLT-2i without heart failure

(N = 25,543)

Underweight

0 (0.0)

18 (0.1)

Normal weight

54 (4.7)

1396 (5.5)

Overweight

229 (19.8)

6149 (24.1)

Obese

855 (73.9)

17,595 (68.9)

Missing

19 (1.6)

385 (1.5)

  1. Data are presented as n(%)
  2. BMI body mass index, SGLT-2i sodium–glucose co‐transporter‐2 inhibitor
  3. aBMI categories closest to first SGLT-2- prescription: underweight, < 18.5 kg/m2; normal, 18.5 − 24.9 kg/m2; overweight, 25.0 − 29.9 kg/m2; obese, > 30 kg/m2
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840